Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
A Metin Gülmezoglu National Perinatal Epidemiology Unit,
Radcliffe Infirmary, Oxford OX2 6HE
Correspondence to: Dr A M Gülmezoglu, United
Kingdom Cochrane Centre, NHS Research and Development Programme,
Summertown Pavilion, Oxford OX2 7LG mgulmezoglu@cochrane.co.uk
The first 150 words of the full text of this article appear below.
Pre-eclampsia is a multisystem disorder associated with
hypertension and proteinuria and is a fairly common complication of pregnancy. Eclampsia, the occurrence of fits with pre-eclampsia, is
rare, but both conditions can have serious consequences for the mother
and infant. Anticonvulsants are given to women with eclampsia to
prevent further fits and to women with pre-eclampsia to prevent the
first fit, thereby improving the outcome for mother and infant.
Clinical practice, however, varies greatly worldwide. In the United
Kingdom diazepam has been popular since the 1970s and phenytoin
since the early 1990s, but the use of magnesium sulphate remains
uncommon.
1 2
Magnesium sulphate has been widely used for
decades in the United States and has recently been acknowledged as the
preferred anticonvulsant for women with eclampsia.3 There
is little evidence to support or refute the use of anticonvulsants in
women with pre-eclampsia.4 We conducted a survey to
determine the current use of